RANCHO DOMINGUEZ, Calif. May 19, 2009 -- Molecular Express (http://www.molecularexpress.com) announced the receipt of SBIR Phase II funding from the National Heart Lung and Blood Institute  (NHLBI) to develop a novel lung surfactant product for treating patients suffering from Acute Lung Injury (ALI) or the Acute Respiratory Distress syndrome (ARDS).  The lung surfactant project will be a multi-institutional collaborative effort between Professors Alan Waring and Frans Walther of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), Professor Robert Notter of the University of Rochester, Professor Adrian Schwan of the University of Guelph and the Molecular Express team.  The Company has also obtained an exclusive license to certain synthetic lung surfactant technology discovered by Professors Waring, Walther, Notter and Schwan.

RANCHO DOMINGUEZ, Calif. May 23, 2008 -- Molecular Express (http://www.molecularexpress.com) announced the award of SBIR Advanced Technology Phase I funding from the NIAID (National Institute of Allergy and Infectious Diseases) to develop an adjuvant system.  This project will focus on anthrax as a model disease and will be a collaborative effort between Professor Zhengrong Cui of Oregon State University, Professor C. Rick Lyons of the University of New Mexico and the Molecular Express team. 
 

October 2007: Dr. Fujii invited to speak at the Western Regional Meeting of the ACS.